CXCL11 and neoplasm: Thus, CXCL10 expression may lead to rapid tumor rejection by recruitment of CXCR3+ T-cells into the nascent tumor, in analogy to immune-competent mice implanted sub-cutaneously with CT26 cells, treated with an CXCL10-CXCL11 fusion chemokine [53].